136 related articles for article (PubMed ID: 30429055)
1. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling.
Sin STK; Li Y; Liu M; Ma S; Guan XY
Gynecol Oncol; 2019 Jan; 152(1):185-193. PubMed ID: 30429055
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY
Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188
[TBL] [Abstract][Full Text] [Related]
3. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Lovly CM; McDonald NT; Chen H; Ortiz-Cuaran S; Heukamp LC; Yan Y; Florin A; Ozretić L; Lim D; Wang L; Chen Z; Chen X; Lu P; Paik PK; Shen R; Jin H; Buettner R; Ansén S; Perner S; Brockmann M; Bos M; Wolf J; Gardizi M; Wright GM; Solomon B; Russell PA; Rogers TM; Suehara Y; Red-Brewer M; Tieu R; de Stanchina E; Wang Q; Zhao Z; Johnson DH; Horn L; Wong KK; Thomas RK; Ladanyi M; Pao W
Nat Med; 2014 Sep; 20(9):1027-34. PubMed ID: 25173427
[TBL] [Abstract][Full Text] [Related]
4. miR-375 Affects the Proliferation, Invasion, and Apoptosis of HPV16-Positive Human Cervical Cancer Cells by Targeting IGF-1R.
Yu X; Zhao W; Yang X; Wang Z; Hao M
Int J Gynecol Cancer; 2016 Jun; 26(5):851-8. PubMed ID: 27206217
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor.
Luo M; Shen D; Zhou X; Chen X; Wang W
Surgery; 2013 Jun; 153(6):836-47. PubMed ID: 23453369
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
[TBL] [Abstract][Full Text] [Related]
8. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
[TBL] [Abstract][Full Text] [Related]
9. Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.
Zhou X; Fang X; Jiang Y; Geng L; Li X; Li Y; Lu K; Li P; Lv X; Wang X
J Hematol Oncol; 2017 Feb; 10(1):37. PubMed ID: 28153033
[TBL] [Abstract][Full Text] [Related]
10. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.
Li L; Wang Y; Peng T; Zhang K; Lin C; Han R; Lu C; He Y
Oncotarget; 2016 Jun; 7(23):34442-52. PubMed ID: 27144340
[TBL] [Abstract][Full Text] [Related]
11. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.
Wei YH; Tang HX; Liao YD; Fu SL; Xu LQ; Chen G; Zhang C; Ju S; Liu ZG; You LK; Yu L; Zhou S
J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):834-841. PubMed ID: 26670433
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK
George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
J Hematol Oncol; 2019 Jul; 12(1):80. PubMed ID: 31340850
[TBL] [Abstract][Full Text] [Related]
13. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
14. 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells.
Kelavkar UP; Cohen C
Neoplasia; 2004; 6(1):41-52. PubMed ID: 15068670
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
16. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
[TBL] [Abstract][Full Text] [Related]
17. Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein.
Warsito D; Lin Y; Gnirck AC; Sehat B; Larsson O
Oncotarget; 2016 Jul; 7(27):42288-42302. PubMed ID: 27275536
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
19. The complex biology of the receptor for the insulin-like growth factor-1.
Romano G
Drug News Perspect; 2003 Oct; 16(8):525-31. PubMed ID: 14668950
[TBL] [Abstract][Full Text] [Related]
20. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
